tiprankstipranks
Trending News
More News >
Renascience Inc. (JP:4889)
:4889
Japanese Market

Renascience Inc. (4889) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Renascience Inc.

(4889)

Rating:51Neutral
Price Target:
Renascience Inc. has a strong financial foundation with low leverage but struggles with profitability and cash flow, affecting its financial performance score. Technical indicators point to a bearish trend, and the high P/E ratio raises valuation concerns. The combination of these factors results in a moderately low overall stock score.

Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)

Renascience Inc. Business Overview & Revenue Model

Company DescriptionRenascience Inc. (4889) is a cutting-edge biotechnology company specializing in the development and commercialization of innovative solutions for regenerative medicine. The company focuses on harnessing the power of stem cell technology and tissue engineering to address unmet medical needs in various therapeutic areas. Renascience Inc. is committed to advancing healthcare by providing transformative products and services that enhance the quality of life for patients worldwide.
How the Company Makes MoneyRenascience Inc. generates revenue primarily through the sale of its proprietary regenerative medicine products and technologies. The company's key revenue streams include direct sales to healthcare providers, licensing agreements with pharmaceutical companies, and strategic partnerships with research institutions. Additionally, Renascience Inc. may receive funding from government grants and private investors to support its research and development activities. The company leverages its advanced scientific capabilities and expertise to maintain a competitive edge in the biotechnology sector, driving sustainable growth and profitability.

Renascience Inc. Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue138.39M194.16M100.55M139.33M209.80M72.00M
Gross Profit133.15M165.64M100.30M80.97M179.82M52.00M
EBITDA-150.88M-250.50M-332.49M-244.65M-80.36M-180.08M
Net Income118.14M-258.33M-335.80M-254.29M-100.05M-184.00M
Balance Sheet
Total Assets1.91B2.09B2.27B2.44B1.07B1.01B
Cash, Cash Equivalents and Short-Term Investments1.84B2.03B2.21B2.39B1.03B980.00M
Total Debt0.00356.10M309.60M199.23M475.65M380.00M
Total Liabilities147.00M482.11M409.76M237.17M505.10M-1.00K
Stockholders Equity1.76B1.61B1.87B2.20B561.53M621.00M
Cash Flow
Free Cash Flow0.00-232.10M-286.87M-231.66M-90.27M-178.31M
Operating Cash Flow0.00-230.52M-284.64M-230.49M-89.25M-178.31M
Investing Cash Flow0.00-1.57M232.00K-296.00K-1.72M-380.70M
Financing Cash Flow0.0046.50M110.37M1.59B135.65M380.00M

Renascience Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2225.00
Price Trends
50DMA
1669.80
Positive
100DMA
1408.87
Positive
200DMA
937.38
Positive
Market Momentum
MACD
91.14
Positive
RSI
62.20
Neutral
STOCH
72.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Positive. The current price of 2225 is above the 20-day moving average (MA) of 2009.25, above the 50-day MA of 1669.80, and above the 200-day MA of 937.38, indicating a bullish trend. The MACD of 91.14 indicates Positive momentum. The RSI at 62.20 is Neutral, neither overbought nor oversold. The STOCH value of 72.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4889.

Renascience Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
¥2.19T12.4112.99%2.33%0.73%7.75%
79
Outperform
$11.74T28.6522.80%3.50%17.96%25.65%
73
Outperform
$2.49T48.753.22%5.35%19.25%294.48%
67
Neutral
¥1.14T24.695.34%3.96%6.42%10.82%
64
Neutral
¥338.68B10.98-2.99%2.59%11.79%-10.11%
58
Neutral
$5.91T20.3117.60%1.89%17.77%49.34%
51
Neutral
¥29.07B256.30
-27.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4889
Renascience Inc.
2,225.00
1,879.00
543.06%
JP:4503
Astellas Pharma
1,365.00
-190.64
-12.25%
JP:4519
Chugai Pharmaceutical Co
6,902.00
664.03
10.64%
JP:4507
Shionogi & Co
2,435.00
335.58
15.98%
JP:4523
Eisai Co
4,000.00
-2,418.78
-37.68%
JP:4568
Daiichi Sankyo Company
3,135.00
-2,659.07
-45.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025